Compare HIW & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | VERA |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 1994 | 2021 |
| Metric | HIW | VERA |
|---|---|---|
| Price | $26.24 | $46.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $31.00 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $811,773,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.19 | $18.53 |
| 52 Week High | $32.76 | $56.05 |
| Indicator | HIW | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 49.43 |
| Support Level | $26.88 | $44.56 |
| Resistance Level | $27.40 | $49.33 |
| Average True Range (ATR) | 0.57 | 2.49 |
| MACD | -0.04 | -0.55 |
| Stochastic Oscillator | 17.31 | 31.19 |
Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.